Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
107,6 USD | +0,49 % | -1,48 % | -2,25 % |
23.04. | ABBOTT LABORATORIES : Bewertung von Daiwa Securities kaufen | ZM |
23.04. | ABBOTT LABORATORIES : Barclays bekräftigt seine Kaufempfehlung | ZM |
Kurzporträt
- Diagnostische Systeme und Instrumente (39,1%);
- vaskuläre Geräte (24,7%): endoprothetische Systeme, Dilatationskatheter, Arterienverschlüsse usw.;
- Ernährungsprodukte (12,1%): pädiatrische Ernährungsprodukte, Nahrungsergänzungsmittel und diätetische Produkte;
- Medizin (8,2%): Anästhetika, antivirale Produkte, Antibiotika, Hemmstoffe, Entzündungshemmer usw.;
- Sonstige (15,9%).
Der Nettoumsatz verteilt sich geografisch wie folgt: Vereinigte Staaten (38,5%), Deutschland (5,8%), China (5,6%), Indien (4,4%), Schweiz (4,1%), Japan (3,8%), Niederlande (2,7%) und andere (35,1%).
Mitarbeiterzahl: 114 000
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Medical Devices
42,1
%
| 14 687 | 33,6 % | 16 887 | 42,1 % | +14,98 % |
Diagnostic Products
24,9
%
| 16 584 | 38,0 % | 9 988 | 24,9 % | -39,77 % |
Nutritional Products
20,3
%
| 7 459 | 17,1 % | 8 154 | 20,3 % | +9,32 % |
Established Pharmaceutical Products
12,6
%
| 4 912 | 11,3 % | 5 066 | 12,6 % | +3,14 % |
Other
0,0
%
| 11 | 0,0 % | 14 | 0,0 % | +27,27 % |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
38,5
%
| 18 142 | 41,6 % | 15 452 | 38,5 % | -14,83 % |
All Other Countries
35,1
%
| 14 841 | 34,0 % | 14 084 | 35,1 % | -5,10 % |
Germany
5,8
%
| 2 340 | 5,4 % | 2 345 | 5,8 % | +0,21 % |
China
5,6
%
| 2 133 | 4,9 % | 2 253 | 5,6 % | +5,63 % |
India
4,4
%
| 1 649 | 3,8 % | 1 750 | 4,4 % | +6,12 % |
Switzerland
4,1
%
| 1 336 | 3,1 % | 1 638 | 4,1 % | +22,60 % |
Japan
3,8
%
| 1 932 | 4,4 % | 1 513 | 3,8 % | -21,69 % |
Netherlands
2,7
%
| - | - | 1 074 | 2,7 % | - |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Robert Ford
CEO | Chief Executive Officer | 50 | 01.01.15 |
Philip Boudreau
DFI | Director of Finance/CFO | 51 | 01.01.97 |
Scott House
CTO | Chief Tech/Sci/R&D Officer | - | 01.01.90 |
Melissa Brotz
IRO | Public Communications Contact | - | - |
Jim Leffelman
PRN | Corporate Officer/Principal | - | - |
Andrea Wainer
PRN | Corporate Officer/Principal | - | 01.01.97 |
Corporate Officer/Principal | - | 01.01.97 | |
Kathryn Collins
LAW | General Counsel | - | 01.01.99 |
John McCoy
AUD | Comptroller/Controller/Auditor | 54 | 01.01.18 |
Hubert Allen
LAW | General Counsel | 58 | 01.01.06 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Daniel Starks
BRD | Director/Board Member | 69 | 16.02.17 |
John Stratton
BRD | Director/Board Member | 63 | 29.06.17 |
Nancy McKinstry
BRD | Director/Board Member | 65 | 09.12.11 |
Robert Alpern
BRD | Director/Board Member | 73 | 10.10.08 |
Michael Roman
BRD | Director/Board Member | 64 | 23.04.21 |
Michael O'Grady
BRD | Director/Board Member | 58 | 28.04.23 |
Robert Ford
CEO | Chief Executive Officer | 50 | 01.01.15 |
Sally Blount
BRD | Director/Board Member | 62 | 09.12.11 |
Michelle Kumbier
BRD | Director/Board Member | 56 | 08.06.18 |
Darren McDew
BRD | Director/Board Member | 63 | 09.09.19 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 1 988 991 783 | 1 725 754 414 ( 86,77 %) | 253 807 494 ( 12,76 %) | 86,77 % |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
ABBOTT INDIA LIMITED 74,99% | 15 934 048 | 74,99% | 5 148 033 415 $ |
76 259 451 | 77,90% | 131 350 041 $ | |
17 949 800 | 51,69% | 45 607 390 $ | |
ALLERGY THERAPEUTICS PLC 2,98% | 142 136 143 | 2,98% | 5 386 960 $ |
Unternehmenskontakt
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
Medical Specialties
| |
Cozart Ltd.
Cozart Ltd. Medical SpecialtiesHealth Technology Cozart Ltd. designs and manufactures diagnostics products. Its products are used to test for the presence of various drugs of abuse, such as opiates, cocaine, amphetamine, methamphetamine and cannabis. The company also offers laboratory services providing screening and confirmation services in samples including oral fluid, urine, and blood. Cozart was founded by Dr. Christopher William Hand and Philip Hand in 1993 and is located in Abingdon, the United Kingdom. |
Medical Specialties
|
Abbott Toxicology Ltd.
Abbott Toxicology Ltd. Medical SpecialtiesHealth Technology Abbott Toxicology Ltd. provides drug and alcohol testing products and services. It offers advisory services and testing capabilities, including laboratory testings, point of care tests and sample types for any biological specimen, including urine, oral fluids, hair and sweat. The company was founded in 2005 and is headquartered in Abingdon, the United Kingdom. |
Medical Specialties
|
Pharmaceuticals: Major
| |
Abbott Established Products Holdings (Gibraltar) Ltd.
| |
Pharmaceuticals: Major
| |
Abbott GmbH (Germany)
Abbott GmbH (Germany) Pharmaceuticals: MajorHealth Technology Abbott GmbH & Co. KG develops and manufactures health care products. It is engaged in the discovery, development, manufacture, and marketing of pharmaceutical, diagnostic, nutritional, and hospital products. It offers pharmaceutical and diagnostic products ranging from prevention and diagnosis to treatment and cure. The company is headquartered in Ludwigshafen, Germany. |
Pharmaceuticals: Major
|
Laboratoires Fournier SAS
Laboratoires Fournier SAS Pharmaceuticals: MajorHealth Technology Laboratoires Fournier SAS manufactures pharmaceutical preparations. The company was founded on July 10, 2007 and is headquartered in Rungis, France. |
Pharmaceuticals: Major
|
Abbott Cardiovascular Systems, Inc.
Abbott Cardiovascular Systems, Inc. Medical SpecialtiesHealth Technology Abbott Cardiovascular Systems, Inc. manufactures medical devices. It also makes cardiac and peripheral vascular repair surgical systems. The company was founded in 1978 and is headquartered in Santa Clara, CA. |
Medical Specialties
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
-2,25 % | 186 Mrd. | |
-1,32 % | 107 Mrd. | |
-3,92 % | 67,57 Mrd. | |
+7,99 % | 50,7 Mrd. | |
+15,74 % | 47,2 Mrd. | |
-0,45 % | 39,72 Mrd. | |
+10,81 % | 27,48 Mrd. | |
+2,34 % | 25,65 Mrd. | |
+13,37 % | 24,97 Mrd. | |
-0,16 % | 24,82 Mrd. |
- Börse
- Aktien
- 850103 Aktie
- Unternehmen Abbott Laboratories